Immatics N.V. Ordinary Shares (IMTX) Stock Price

IMTXStock

$9.24+52.72%52W

Market Cap$1.26B

P/E79.47x

PEG Ratio—

Div yield—

Beta1.34

IMTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-23.91%

Price vs S&P 500 (4W)-3.57%

VGM Score36.38

P/E Ratio (Annual)79.47x

Book Value / Share (Quarterly)$3.89

P/TBV (Annual)2.53x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.63%

Cash Flow / Share (Quarterly)$-1.61

Price vs S&P 500 (YTD)-29.20%

Net Profit Margin (TTM)-574.86%

EPS (TTM)$-2.00

10-Day Avg Trading Volume0.52M

EPS Excl Extra (TTM)$-2.00

Revenue Growth (5Y)9.05%

EPS (Annual)$-1.87

ROI (Annual)-39.31%

Net Profit Margin (5Y Avg)-163.79%

Cash / Share (Quarterly)$3.87

Revenue Growth QoQ (YoY)-59.04%

P/E Normalized (Annual)79.47x

ROA (Last FY)-34.93%

Revenue Growth TTM (YoY)-74.13%

EBITD / Share (TTM)$-1.86

ROE (5Y Avg)-90.19%

Operating Margin (TTM)-570.30%

Cash Flow / Share (Annual)$-1.60

P/B Ratio2.45x

P/B Ratio (Quarterly)2.51x

Net Income / Employee (Annual)$-804,404

EV / Revenue (TTM)22.21x

Net Interest Coverage (TTM)-11.09x

ROA (TTM)-39.13%

EV / EBITDA (TTM)22.45x

EPS Incl Extra (Annual)$-1.87

Current Ratio (Annual)11.72x

Quick Ratio (Quarterly)8.61x

3-Month Avg Trading Volume0.47M

52-Week Price Return52.72%

EV / Free Cash Flow (Annual)8.67x

Revenue / Employee (TTM)$152,759

Tangible BV / Share (Quarterly)$3.88

P/S Ratio (Annual)23.09x

Asset Turnover (Annual)0.09x

52-Week High$14.48

Operating Margin (5Y Avg)-164.18%

EPS Excl Extra (Annual)$-1.87

CapEx CAGR (5Y)-1.93%

Tangible BV CAGR (5Y)41.06%

26-Week Price Return-12.66%

Quick Ratio (Annual)11.42x

13-Week Price Return-21.43%

Total Debt / Equity (Annual)0.03x

Current Ratio (Quarterly)8.78x

Enterprise Value$966.78M

Revenue / Share Growth (5Y)-9.56%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)21.07%

Revenue / Employee (Annual)$197,687

Pretax Margin (Annual)-411.13%

Cash / Share (Annual)$4.09

3-Month Return Std Dev51.20%

Net Income / Employee (TTM)$-877,924

ROE (Last FY)-40.58%

Net Interest Coverage (Annual)-3.31x

EPS Basic Excl Extra (Annual)$-1.87

P/FCF (TTM)15.97x

Receivables Turnover (TTM)7.65x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-2.00

Receivables Turnover (Annual)8.07x

ROI (TTM)-45.49%

P/S Ratio (TTM)29.89x

Pretax Margin (5Y Avg)-164.17%

Revenue / Share (Annual)$0.46

Tangible BV / Share (Annual)$4.20

Price vs S&P 500 (52W)34.41%

Year-to-Date Return-17.24%

5-Day Price Return-4.40%

EPS Normalized (Annual)$-1.87

ROA (5Y Avg)-19.11%

Net Profit Margin (Annual)-407.01%

Month-to-Date Return0.35%

Cash Flow / Share (TTM)$-1.23

EBITD / Share (Annual)$-1.65

Operating Margin (Annual)-377.11%

LT Debt / Equity (Annual)5.82x

ROI (5Y Avg)-67.06%

LT Debt / Equity (Quarterly)6.45x

EPS Basic Excl Extra (TTM)$-2.00

P/TBV (Quarterly)2.52x

P/B Ratio (Annual)2.52x

Pretax Margin (TTM)-577.38%

Book Value / Share (Annual)$4.21

Price vs S&P 500 (13W)-24.22%

Beta1.34x

P/FCF (Annual)11.87x

Revenue / Share (TTM)$0.32

ROE (TTM)-47.09%

52-Week Low$5.89

vGradeC

gGradeD

mGradeC

vgmGradeD

IMTX Earnings Surprise History

Q2 25-0.79est. -0.42

Q3 25-0.57est. -0.53

Q4 25-0.39est. -0.56

Q1 26-0.59est. -0.51

Q2 26-0.62est. -0.55

IMTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.35

4.38

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Immatics N.V. Ordinary Shares

Immatics NV is a biotechnology company developing T-cell redirecting immunotherapies for cancer treatment. The company generates revenue primarily through strategic partnerships and collaboration agreements with pharmaceutical and biotechnology firms. The United States represents its largest revenue source.